Treating type 2 diabetes in COVID-19 patients: the potential benefits of injective therapies.
Cardiovasc Diabetol
; 19(1): 115, 2020 07 22.
Article
in English
| MEDLINE | ID: covidwho-662457
ABSTRACT
The coronavirus disease 2019 (COVID-19) has been declared as pandemic by the World Health Organization and is causing substantial morbidity and mortality all over the world. Type 2 diabetes, hypertension, and cardiovascular disease significantly increase the risk for hospitalization and death in COVID-19 patients. Hypoglycemia and hyperglycemia are both predictors for adverse outcomes in hospitalized patients. An optimized glycemic control should be pursued in patients with diabetes and SARS-CoV-2 infection in order to reduce the risk of severe COVID-19 course. Both insulin and GLP-1RAs have shown optimal glucose-lowering and anti-inflammatory effects in type 2 diabetic patients and may represent a valid therapeutic option to treat asymptomatic and non-critically ill COVID-19 diabetic patients.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Blood Glucose
/
Coronavirus Infections
/
Diabetes Mellitus, Type 2
/
Incretins
/
Betacoronavirus
/
Hypoglycemic Agents
/
Insulin
Type of study:
Diagnostic study
/
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Cardiovasc Diabetol
Journal subject:
Vascular Diseases
/
Cardiology
/
Endocrinology
Year:
2020
Document Type:
Article
Affiliation country:
S12933-020-01090-9
Similar
MEDLINE
...
LILACS
LIS